Keensight Capital Acquires Majority Stake in Isto Biologics

Isto Biologics (TSCP Portfolio) Acquires TheraCell

April 5, 2022

Medical Devices

Isto Biologics, a portfolio company of Thompson Street Capital Partners, has acquired TheraCell, a Los Angeles–based regenerative medicine company known for its TheraFuze DBF bone-fiber technology. The deal expands Isto's orthobiologics product portfolio—adding TheraCell's proprietary spinal repair technologies to Isto's Influx line—and aims to accelerate surgical adoption through Isto's commercial and clinical teams. Terms were not disclosed.

Keensight Capital Takes Majority Stake in Adista from Equistone

June 15, 2021

IT Services

Keensight Capital has signed an agreement to acquire a majority stake in Adista, the leading French alternative B2B hosted services operator, taking over Equistone Partners Europe as majority shareholder alongside FEF and Adista management. Adista — a French IT and telecom services provider with more than 720 employees and 35 branches, €153m in revenues for the 12 months to 31/12/2020 and a target of €300m by 2025 — will be supported by Keensight to accelerate organic growth and pursue external growth / capability expansion.

Keensight Capital Invests in CatSci Ltd

January 15, 2022

Healthcare Services

Keensight Capital has made a growth investment in CatSci Ltd, a Cardiff‑headquartered Contract Research Organisation (CRO) formed as a 2010 spin‑out from AstraZeneca. Keensight will invest alongside CatSci founders, senior management and employees to support the company's continued growth and capability expansion in small‑molecule and oligonucleotide CMC development and scale‑up.

Keensight Capital Acquires Majority Stake in ACTICO Group from Bregal Unternehmerkapital Funds

March 13, 2025

Software

Keensight Capital has signed an agreement to acquire a majority stake in ACTICO Group, a Germany-headquartered provider of regulatory compliance, decision automation, and credit risk management software. Existing shareholder Bregal Unternehmerkapital Funds will partially exit and reinvest alongside Keensight; Keensight plans to support ACTICO's international expansion and product roadmap, with the deal expected to close in May 2025 subject to regulatory approvals.

Keensight Capital Acquires Majority Stake in Bedfont Scientific Ltd.

October 13, 2025

Medical Devices

Keensight Capital has acquired a majority stake in Bedfont Scientific Ltd., a UK-based designer and manufacturer of non-invasive breath analysis medical devices. The investment will support Bedfont's international expansion, product innovation and potential M&A-driven growth while existing shareholders reinvest alongside Keensight.

Keensight Capital Acquires Majority Stake in BYG4lab

July 22, 2022

Software

Keensight Capital has acquired a majority stake in BYG4lab, a France-headquartered provider of data management software for medical laboratories. The PE firm will support BYG4lab's international expansion (Europe and North America), product diversification and accelerated growth both organically and via acquisitions.